Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts give Karyopharm a consensus "Moderate Buy" rating from eight contributors (six buys, one strong buy, one sell) with an average 12‑month target of $15.43, and mixed recent price‑target moves such as Piper Sandler raising its objective to $16 while HC Wainwright cut theirs to $8.
• The stock trades around $8.66 (market cap ~$195M) and remains unprofitable, but Karyopharm slightly beat the last quarter's estimates (EPS ‑$2.23 vs. ‑$2.26; revenue $34.08M vs. $33.16M); institutional investors own 66.44% of the shares with several funds materially increasing positions.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $15.4286.

Several equities research analysts have commented on the company. Piper Sandler reiterated an "overweight" rating and set a $16.00 price objective (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday. HC Wainwright dropped their price target on Karyopharm Therapeutics from $15.00 to $8.00 and set a "buy" rating for the company in a research report on Wednesday, March 25th. Cantor Fitzgerald began coverage on Karyopharm Therapeutics in a report on Thursday, February 5th. They issued an "overweight" rating on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Finally, Robert W. Baird decreased their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 25th.

Institutional Trading of Karyopharm Therapeutics

Hedge funds have recently modified their holdings of the stock. Ikarian Capital LLC raised its stake in shares of Karyopharm Therapeutics by 1,897.9% in the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company's stock valued at $4,008,000 after acquiring an additional 517,297 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Karyopharm Therapeutics by 101.2% during the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company's stock worth $1,382,000 after purchasing an additional 94,445 shares during the last quarter. Bridgeway Capital Management LLC grew its holdings in shares of Karyopharm Therapeutics by 88.9% during the fourth quarter. Bridgeway Capital Management LLC now owns 65,873 shares of the company's stock worth $485,000 after purchasing an additional 31,000 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter worth about $439,000. Finally, State Street Corp grew its holdings in shares of Karyopharm Therapeutics by 27.2% during the fourth quarter. State Street Corp now owns 58,942 shares of the company's stock worth $434,000 after buying an additional 12,600 shares during the last quarter. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $8.66 on Tuesday. The stock has a market capitalization of $195.20 million, a price-to-earnings ratio of -0.52 and a beta of 0.40. Karyopharm Therapeutics has a twelve month low of $3.65 and a twelve month high of $10.99. The stock has a 50-day moving average of $8.09 and a 200 day moving average of $7.04.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its quarterly earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.03. The business had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. Equities analysts predict that Karyopharm Therapeutics will post -4.6 EPS for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics NASDAQ: KPTI is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company's lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm's pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.